Guillain-Barre Syndrome Drug Pipeline Analysis Report 2025
Description
Guillain-Barre syndrome (GBS) is a rare autoimmune disorder in which the body's immune system attacks the peripheral nerves, leading to muscle weakness and paralysis. It accounts for approximately 0.38 to 2.53 cases per 100,000 person-years worldwide. There is a significant unmet clinical need for improved therapies, as current treatment options, such as intravenous immunoglobulin (IVIG) and plasma exchange, have limitations. The growing emphasis on novel immunomodulatory approaches and targeted Guillain-Barre syndrome therapeutic products is expected to drive pipeline growth. Promising drug candidates, including monoclonal antibodies and complement inhibitors, are under investigation to improve patient outcomes.
Report Coverage
The Guillain-Barre Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Guillain-Barre syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Guillain-Barre syndrome. The Guillain-Barre syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Guillain-Barre syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Guillain-Barre syndrome treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Guillain-Barre syndrome.
Guillain-Barre Syndrome Drug Pipeline Outlook
Guillain-Barre syndrome is a rare autoimmune disorder where the body's immune system attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. It often follows an infection, such as a respiratory or gastrointestinal illness, which triggers the immune response that damages nerve tissues.
Treatment for Guillain-Barre syndrome focuses on managing symptoms and accelerating recovery. Current therapies include intravenous immunoglobulin (IVIG) and plasma exchange, both aimed at reducing the immune response. Supportive care, such as respiratory assistance, may be necessary for severe cases, while physical therapy helps in regaining strength and mobility.
Guillain-Barre Syndrome Epidemiology
A 2024 study reports that Guillain-Barré syndrome incidence varies globally, ranging from 0.38 to 2.53 cases per 100,000 individuals annually. European and North American populations show annual incidences between 0.84 and 1.91 per 100,000, while incidences in Asian populations, such as Japan, are notably lower at 0.44 per 100,000 individuals. These epidemiological findings inform ongoing therapeutic developments for Guillain-Barré syndrome.
Guillain-Barre Syndrome Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Guillain-Barre syndrome drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phases II and IV encompass a significant share of the total Guillain-Barre syndrome clinical trials
Guillain-Barre Syndrome – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Guillain-Barre syndrome pipeline analysis include monoclonal antibodies, small molecules, gene therapies, biologics, plasma-derived therapies, and others. The Guillain-Barre syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Guillain-Barre syndrome.
Guillain-Barre Syndrome Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the Guillain-Barre syndrome drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed Guillain-Barre syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Guillain-Barre syndrome clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Guillain-Barre syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Guillain-Barre syndrome drug candidates.
Drug: ANX005
The Phase III study, sponsored by Annexon, Inc., evaluates the efficacy and safety of ANX005, a first-in-class C1q blocking antibody, in Guillain-Barré syndrome (GBS). The trial met its primary endpoint, demonstrating a 2.4-fold improvement in Guillain-Barré syndrome -disability scale at week 8. ANX005 showed early and sustained benefits, including improved muscle strength, reduced nerve damage, and shorter ventilation dependency.
Drug: Efgartigimod
The Phase III clinical trial, sponsored by Chafic Karam at the University of Pennsylvania, evaluates the safety and efficacy of Efgartigimod in Guillain-Barré syndrome (GBS) patients. The study aims to determine whether Efgartigimod improves patient outcomes. The study is expected to be completed by May 2027 and will enroll around 30 participants.
Drug: Imlifidase
Hansa Biopharma’s investigational drug, Imlifidase, has shown promising results in treating Guillain-Barré syndrome (GBS). The objective of this Phase II study (15-HMedIdeS-09) was to examine the drug’s efficacy in improving motor function. Patients receiving Imlifidase with IVIg regained independent walking in 16 days, nearly six weeks faster than those treated with IVIg alone in the IGOS study.
Reasons To Buy This Report
The Guillain-Barre Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Guillain-Barre syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Guillain-Barre syndrome collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Guillain-Barre Syndrome – Pipeline Insight Report
Global Guillain-Barre Syndrome Treatment Market
Global Nerve Repair and Regeneration Market
Global Clinical Trials Market
Report Coverage
The Guillain-Barre Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Guillain-Barre syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Guillain-Barre syndrome. The Guillain-Barre syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Guillain-Barre syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Guillain-Barre syndrome treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Guillain-Barre syndrome.
Guillain-Barre Syndrome Drug Pipeline Outlook
Guillain-Barre syndrome is a rare autoimmune disorder where the body's immune system attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. It often follows an infection, such as a respiratory or gastrointestinal illness, which triggers the immune response that damages nerve tissues.
Treatment for Guillain-Barre syndrome focuses on managing symptoms and accelerating recovery. Current therapies include intravenous immunoglobulin (IVIG) and plasma exchange, both aimed at reducing the immune response. Supportive care, such as respiratory assistance, may be necessary for severe cases, while physical therapy helps in regaining strength and mobility.
Guillain-Barre Syndrome Epidemiology
A 2024 study reports that Guillain-Barré syndrome incidence varies globally, ranging from 0.38 to 2.53 cases per 100,000 individuals annually. European and North American populations show annual incidences between 0.84 and 1.91 per 100,000, while incidences in Asian populations, such as Japan, are notably lower at 0.44 per 100,000 individuals. These epidemiological findings inform ongoing therapeutic developments for Guillain-Barré syndrome.
Guillain-Barre Syndrome Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Guillain-Barre syndrome drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Biologics
- Plasma-derived Therapies
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phases II and IV encompass a significant share of the total Guillain-Barre syndrome clinical trials
Guillain-Barre Syndrome – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Guillain-Barre syndrome pipeline analysis include monoclonal antibodies, small molecules, gene therapies, biologics, plasma-derived therapies, and others. The Guillain-Barre syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Guillain-Barre syndrome.
Guillain-Barre Syndrome Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the Guillain-Barre syndrome drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed Guillain-Barre syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Guillain-Barre syndrome clinical trials:
- Argenx
- Annexon, Inc.
- Hansa Biopharma AB
- Nihon Pharmaceutical Co., Ltd.
- Alexion Pharmaceuticals, Inc.
- CuraVac
- Grifols S A
- Octapharma AG
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Guillain-Barre syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Guillain-Barre syndrome drug candidates.
Drug: ANX005
The Phase III study, sponsored by Annexon, Inc., evaluates the efficacy and safety of ANX005, a first-in-class C1q blocking antibody, in Guillain-Barré syndrome (GBS). The trial met its primary endpoint, demonstrating a 2.4-fold improvement in Guillain-Barré syndrome -disability scale at week 8. ANX005 showed early and sustained benefits, including improved muscle strength, reduced nerve damage, and shorter ventilation dependency.
Drug: Efgartigimod
The Phase III clinical trial, sponsored by Chafic Karam at the University of Pennsylvania, evaluates the safety and efficacy of Efgartigimod in Guillain-Barré syndrome (GBS) patients. The study aims to determine whether Efgartigimod improves patient outcomes. The study is expected to be completed by May 2027 and will enroll around 30 participants.
Drug: Imlifidase
Hansa Biopharma’s investigational drug, Imlifidase, has shown promising results in treating Guillain-Barré syndrome (GBS). The objective of this Phase II study (15-HMedIdeS-09) was to examine the drug’s efficacy in improving motor function. Patients receiving Imlifidase with IVIg regained independent walking in 16 days, nearly six weeks faster than those treated with IVIg alone in the IGOS study.
Reasons To Buy This Report
The Guillain-Barre Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Guillain-Barre syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Guillain-Barre syndrome collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Guillain-Barre Syndrome – Pipeline Insight Report
- Which companies/institutions are leading the Guillain-Barre syndrome drug development?
- What is the efficacy and safety profile of Guillain-Barre syndrome pipeline drugs?
- Which company is leading the Guillain-Barre syndrome pipeline development activities?
- What is the current Guillain-Barre syndrome commercial assessment?
- What are the opportunities and challenges present in the Guillain-Barre syndrome drug pipeline landscape?
- What is the efficacy and safety profile of Guillain-Barre syndrome pipeline drugs?
- Which company is conducting major trials for Guillain-Barre syndrome drugs?
- Which companies/institutions are involved in Guillain-Barre syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Guillain-Barre syndrome?
Global Guillain-Barre Syndrome Treatment Market
Global Nerve Repair and Regeneration Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Guillain-Barre Syndrome
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Guillain-Barre Syndrome
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Guillain-Barre Syndrome: Epidemiology Snapshot
- 5.1 Guillain-Barre Syndrome Incidence by Key Markets
- 5.2 Guillain-Barre Syndrome – Patients Seeking Treatment in Key Markets
- 6 Guillain-Barre Syndrome: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Guillain-Barre Syndrome: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Guillain-Barre Syndrome, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Guillain-Barre Syndrome Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Guillain-Barre Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: ANX005
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Guillain-Barre Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Efgartigimod
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Imlifidase
- 11.2.3 Other Drugs
- 12 Guillain-Barre Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Guillain-Barre Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Guillain-Barre Syndrome, Key Drug Pipeline Companies
- 14.1 Argenx
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Annexon, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Hansa Biopharma AB
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Nihon Pharmaceutical Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Alexion Pharmaceuticals, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 CuraVac
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Grifols S A
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Octapharma AG
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
